Following several development and licensing collaborations, Boehringer Ingelheim has acquired Saiba Animal Health to strengthen its animal health R&D pipeline, specifically in the fast-growing pet therapeutics category. The Swiss startup specializes in the development of Virus-Like Particles-based therapeutic vaccines targeting major unmet medical needs in veterinary medicine.
